TRACON Pharmaceuticals’ TRC105 Treatment Achieves Ongoing Complete Response In Cancer Patient

TRACON Pharmaceuticals (TCON), a biopharmaceutical company, said a Phase 2 clinical trial of its TRC105 in a patient with persistent and unresectable metastatic choriocarcinoma showed a decrease in the disease marker indicating an ongoing complete response.

The company said disease marker Beta human chorionic gonadotropin decreased from greater than 3,000 IU/L at treatment initiation to less than 1 IU/L from cycles 4 through 7. The patient was treated with TRC105 dosed 10 mg/kg weekly in combination with Avastin dosed 10 mg/kg every other week.


Related posts

Leave a Comment